Isavuconazonium: First Global Approval

A Phase 2, Randomized, Double-Blind, Multicenter Trial To Evaluate the Safety and Efficacy of Three Dosing Regimens of Isavuconazole Compared with Fluconazole in Patients with Uncomplicated Esophageal Candidiasis

(2015) J. Viljoen et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Safety and Pharmacokinetics of Isavuconazole as Antifungal Prophylaxis in Acute Myeloid Leukemia Patients with Neutropenia: Results of a Phase 2, Dose Escalation Study

(2015) Oliver A. Cornely et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Isavuconazole Therapy Protects Immunosuppressed Mice from Mucormycosis

(2014) Guanpingsheng Luo et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Isavuconazole Pharmacodynamic Target Determination for Candida Species in anIn VivoMurine Disseminated Candidiasis Model

(2013) Alexander J. Lepak et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Isavuconazole (BAL4815) Pharmacodynamic Target Determination in anIn VivoMurine Model of Invasive Pulmonary Aspergillosis against Wild-Type andcyp51Mutant Isolates of Aspergillus fumigatus

(2013) Alexander J. Lepak et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Isavuconazole: A Comprehensive Review of Spectrum of Activity of a New Triazole

(2010) George R. Thompson et al.   MYCOPATHOLOGIA

Effect of Mild and Moderate Liver Disease on the Pharmacokinetics of Isavuconazole after Intravenous and Oral Administration of a Single Dose of the Prodrug BAL8557

(2009) A. Schmitt-Hoffmann et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Pharmacokinetics and Pharmacodynamics of a Novel Triazole, Isavuconazole: Mathematical Modeling, Importance of Tissue Concentrations, and Impact of Immune Status on Antifungal Effect

(2009) P. A. Warn et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Efficacy of isavuconazole, voriconazole and fluconazole in temporarily neutropenic murine models of disseminated Candida tropicalis and Candida krusei

(2008) J. Majithiya et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY